DA Davidson maintains Nordson stock Buy rating, $285 target

DA Davidson reaffirmed its Buy rating and $285 price target for Nordson (NDSN) after the company's Q2 2025 results exceeded expectations, driven by strong organic sales growth in its Adhesive Dispensing Systems segment and higher margins; Nordson reported EPS of $2.42 on revenue of $683 million, surpassing forecasts, and issued above-consensus Q3 guidance, projecting sales between $710 million and $750 million and adjusted EPS of $2.55 to $2.75; the company is also divesting certain medical contract manufacturing product lines to enhance growth and margins.

Analysis

DA Davidson has reaffirmed its Buy rating and $285.00 price target for Nordson (NASDAQ:NDSN) following strong second-quarter fiscal year 2025 results. Nordson reported earnings per share (EPS) of $2.42, surpassing analyst forecasts of $2.36, and revenue of $683 million, a 5% year-over-year increase, also exceeding expectations. This performance was driven by robust organic sales growth in the Adhesive Dispensing Systems (ATS) segment, higher margins, and the successful integration of the Atrion acquisition, which is outperforming initial projections. InvestingPro data highlights Nordson's financial health with a P/E ratio of 24.77, impressive gross profit margins of 55.15%, an Altman Z-Score of 8.38, and a notable 46 consecutive years of dividend payments. The company's inbound order activity strengthened, leading to a 5% quarter-over-quarter increase in backlog. Nordson issued optimistic guidance for the third quarter of fiscal year 2025, projecting sales between $710 million and $750 million and adjusted EPS of $2.55 to $2.75, both above DA Davidson’s model at the midpoint. Despite this strong quarterly performance and outlook, Nordson maintained its annual guidance, which brackets consensus expectations, suggesting a degree of caution regarding full-year projections. Strategically, Nordson is divesting certain product lines within its medical contract manufacturing business, a move anticipated to close in Q4 2025 and aimed at enhancing its growth profile and improving margins.

Key Decisions for Investors

• Investors should consider Nordson's strong Q2 performance, positive Q3 guidance, and reaffirmed Buy rating as supportive of a constructive outlook, particularly given its consistent dividend history and robust margins.
• Monitor the execution of the planned divestiture in the medical contract manufacturing segment and the continued performance of the Atrion acquisition, as these are key catalysts for future margin expansion and growth.
• Note the company's decision to maintain full-year guidance despite the Q2 beat, suggesting a balanced risk assessment might be prudent until further evidence of sustained outperformance across all segments is clear.